See the raw experimental evidence behind an author's publications and reproducibility signals.
Press Enter ↵ to solve
Fuel Your Discoveries
"Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less."
- Marie Curie
Quick Explanation
Copied
Author review (science strength): G. Keller
Based on the provided publication record, the strongest signal is in clinical cancer genetics—especially germline CDH1 / HDGC—with one highly cited JAMA Oncology paper and guideline-level work in J Med Genet. Other earlier papers span genetics/oncology and plant/physiology, suggesting either a multi-domain research history or ambiguous author disambiguation risk.
Science-focused, skeptical, evidence-weighted critique of scientific strength based on the supplied OpenAlex snapshot and the cited DOIs listed therein.
1) Evidence map (what the record shows)
The provided author record clusters strongly around cancer genetics topics (notably CDH1, hereditary diffuse gastric cancer (HDGC), penetrance/risk estimation), with multiple highly cited outputs concentrated in 2015.
Below I evaluate *scientific strength signals* visible from the supplied abstracts/metadata. Full critique would require full-text methods, raw data, and statistical details (which are not provided here).
3.1 JAMA Oncology (2015): large HDGC mutation-carrier series
The supplied abstract claims it is “the largest reported series” of CDH1 mutation carriers, aiming to provide “more precise estimates of age-associated risks” to improve counseling of unaffected carriers. Large sample size and clinical-genetics focus often reduce (but do not eliminate) uncertainty in penetrance estimates.
Guideline/clinical counseling impact typically requires careful variant ascertainment, age-standardization, and statistical modeling of cumulative risk; however those details are not visible in the snippet.
Confidence note: moderate that the record corresponds to high-quality clinical genetics work, because the abstract-level claims align with what high-citation penetrance papers usually involve—but exact rigor cannot be verified without methods and data.
3.2 J Med Genet (2015): updated clinical guidelines for germline CDH1
The supplied abstract states germline CDH1 mutations confer high lifetime risk for diffuse gastric and lobular breast cancers and that a multidisciplinary workshop addressed genetic testing, surgery, surveillance, pathology reporting, and patient perspective.
Guidelines can be scientifically valuable when they reflect systematic evidence assessment and transparent evidence strength grading. But without the full guideline document structure, we cannot judge whether the recommendations reflect high-quality evidence versus expert consensus.
Skeptical lens: guideline synthesis can be sensitive to publication bias, selection bias in the evidence base, and assumptions about transfers of risk across populations. Those failure modes can’t be fully assessed from metadata alone.
3.3 Human Molecular Genetics (2009): germline CDH1 deletions in HDGC
The supplied abstract distinguishes point/small frameshift mutations (30–50% detection rate in HDGC families) and tests whether genomic rearrangements (deletions) can be found in HDGC.
Structural variant detection can materially affect penetrance and risk estimates and the fraction of “mutation-negative” families.
Confidence note: moderate that this is mechanistically relevant clinical genetics science, but again, actual laboratory assays, validation, and potential batch effects are not provided.
4) Critical checks: what could mislead this record?
Author disambiguation risk: The snapshot mixes oncology genetics with plant hormone/mitosis and botany/ethylene studies. That may indicate multi-domain work, but could also reflect homonyms (different “G. Keller” individuals). Without ORCID or institution history, misattribution remains a plausible blind spot.
Abstract-level visibility: Strong conclusions about rigor (e.g., model assumptions for penetrance, confidence intervals, censoring handling, family ascertainment bias) require full methods and raw results. The provided material is insufficient to fully audit statistical rigor.
Publication bias / impact bias: Citation counts correlate with relevance and dissemination, not necessarily with methodological quality. Highly cited guideline/series papers can still have limitations (e.g., selection of high-risk families, reliance on incomplete clinical records).
If new evidence were to disprove aspects of these results, it would likely come from: (i) re-analysis of penetrance with independent cohorts; (ii) improved ascertainment correction; (iii) independent replication of deletion/variant detection rates; (iv) population-specific modifier variants changing risk.
5) What the evidence suggests about scientific strength
Strengths (most supported by provided record)
High clinical-genetics relevance: Multiple anchor works center on germline CDH1 and HDGC biology/risks, implying expertise in variant interpretation and cohort synthesis, consistent with the supplied focus topics.
Contribution to synthesis artifacts: A guideline workshop update suggests ability to translate evidence into standardized clinical practice (which typically requires careful evidence integration and consensus building).
Limitations / uncertainties
Rigor can’t be verified here: Without methods, it’s not possible to audit statistical modeling quality, handling of ascertainment bias, genotype calling/validation, or pathology reporting consistency.
Domain mixing: Plant/physiology papers in the same author slot may be real, but are also a common signature of homonym conflation in bibliographic databases.
Penetrance model choice (e.g., parametric survival models), handling of censoring, missing ages, and family structure.
Replication: whether independent cohorts were used for confirmatory penetrance or deletion frequency estimates.
For guidelines: whether evidence grading was systematic and whether recommendations were updated based on explicit decision rules.
Notes on scope: This review is limited to the information explicitly present in the supplied snapshot (titles/years and the short abstract excerpts) plus the DOIs provided there. A full raw-data audit would require full-text methods, supplementary tables, and (when available) cohort-level raw outputs.
Feedback:
Updated: April 15, 2026
BGPT Author Review
Scientific Quality
60%
Moderate scientific strength based on the provided record: multiple cancer-genetics anchor papers around germline CDH1/HDGC suggest real expertise and contributions to clinically impactful synthesis (large series and guideline-level work). However, rigor cannot be audited from snippets alone, and the mixed appearance of plant/physiology and oncology in the same author slot raises substantial author-disambiguation uncertainty (a major blind spot). Citation impact suggests relevance but not guaranteed methodological superiority.
Communication Quality
70%
The record suggests author participation in guideline and large cohort publications, which typically require clear scientific writing and consensus framing. But the provided material contains only brief abstract snippets; without full text, I can’t fully evaluate clarity, structure, or transparency.
Author Novelty
50%
The biggest visible impact appears to come from larger datasets and updated synthesis rather than obviously novel mechanistic discoveries (at least as reflected by the abstracts). Novelty is therefore assessed as moderate-low from this limited evidence set.
Scientific Rigor
50%
Insufficient direct evidence of statistical and experimental rigor (methods, validation, model assumptions, raw data handling are not provided). The topics (penetrance estimation, structural variant detection, guideline synthesis) are areas where rigor varies widely across studies; without full-text verification, rigor can only be rated as moderate/uncertain. Also, author conflation risk could distort perceived rigor attributable to the person.
Not applicable: the prompt is an author-scientific-strength review, not a sequence/structure/data-analysis task requiring bioinformatics computation.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“Cohort size alone explains the high citation impact.” Likely false: impact usually also reflects clinical relevance, rigor, and how the work became a reference standard; however, the record doesn’t demonstrate those components directly.
“The plant/physiology entries indicate identical mechanistic expertise transferable to CDH1 penetrance modeling.” Plausible but not supported: different domains may reflect different individuals or unrelated collaborations; without identity confirmation, the inference is weak.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Analysis Wizard
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
